SL
TAK icon

Salomon & Ludwin’s Takeda Pharmaceutical TAK Stock Holding History

Salomon & Ludwin’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.2K Sell
1,204
-1,387
-54% -$23K ﹤0.01% 1181
2026
Q1 		$48.6K Buy
2,591
+1,459
+129% +$25.6K ﹤0.01% 492
2025
Q4 		$17.8K Sell
1,132
-27
-2% -$386 ﹤0.01% 997
2025
Q3 		$16.9K Buy
1,159
+1,118
+2,727% +$16.6K ﹤0.01% 944
2025
Q2 		$632 Buy
+41
New +$606 ﹤0.01% 809

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Salomon & Ludwin's TAK Position: Q2 2026 in Review

Salomon & Ludwin reduced its Takeda Pharmaceutical (TAK) stake by 54% in Q2 2026, selling an estimated $23K and leaving 1,204 shares worth $19.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1181.

Salomon & Ludwin first reported a position in TAK in Q2 2025 and has held it in 5 quarters since. The position peaked at $48.6K in Q1 2026. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Salomon & Ludwin held 1,204 shares of Takeda Pharmaceutical worth $19.2K as of Q2 2026.
  • Salomon & Ludwin sold 1,387 Takeda Pharmaceutical shares in Q2 2026, an estimated $23K.
  • Takeda Pharmaceutical made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #1181 holding.
  • Salomon & Ludwin first reported a position in Takeda Pharmaceutical in Q2 2025 and has held it in 5 quarters since.
  • Salomon & Ludwin's Takeda Pharmaceutical position peaked at $48.6K in Q1 2026.
  • 378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.